Cara Therapeutics Inc [CARA] stock is trading at $0.29, up 8.28%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CARA shares have gain 8.65% over the last week, with a monthly amount glided 0.70%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Cara Therapeutics Inc [NASDAQ: CARA] stock has seen the most recent analyst activity on June 13, 2024, when Stifel downgraded its rating to a Hold and also revised its price target to $1 from $6. Previously, Needham downgraded its rating to Hold on June 13, 2024. On June 13, 2024, downgrade downgraded it’s rating to Neutral. Canaccord Genuity downgraded its rating to a Hold and decreased its price target to $1 on June 13, 2024. BofA Securities downgraded its rating to a Underperform and reduced its price target to $6 on March 08, 2023. JP Morgan upgraded its rating to Overweight for this stock on March 08, 2022, and upped its price target to $20.
Cara Therapeutics Inc [CARA] stock has fluctuated between $0.24 and $1.40 over the past year. Currently, Wall Street analysts expect the stock to reach $14.5 within the next 12 months. Cara Therapeutics Inc [NASDAQ: CARA] shares were valued at $0.29 at the most recent close of the market. An investor can expect a potential return of 4900.0% based on the average CARA price forecast.
Analyzing the CARA fundamentals
Cara Therapeutics Inc [NASDAQ:CARA] reported sales of 11.00M for the trailing twelve months, which represents a drop of -85.71%. Gross Profit Margin for this corporation currently stands at 0.73% with Operating Profit Margin at -9.47%, Pretax Profit Margin comes in at -10.1%, and Net Profit Margin reading is -10.1%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.41 and Total Capital is -1.78. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.44.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.2635 points at the first support level, and at 0.2380 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3110, and for the 2nd resistance point, it is at 0.3330.
Ratios To Look Out For
For context, Cara Therapeutics Inc’s Current Ratio is 4.59. Also, the Quick Ratio is 4.48, while the Cash Ratio stands at 3.54. Considering the valuation of this stock, the price to sales ratio is 1.44, the price to book ratio is 1.37.
Transactions by insiders
Recent insider trading involved Posner Christopher, PRESIDENT AND CEO, that happened on Aug 01 ’24 when 4149.0 shares were sold. PRESIDENT AND CEO, Posner Christopher completed a deal on May 02 ’24 to sell 3936.0 shares. Meanwhile, CHIEF MEDICAL OFFICER Goncalves Joana sold 2753.0 shares on Apr 05 ’24.
